Marapharm Ventures Inc. (“Marapharm”) is pleased to announce that Marapharm has been invited by the CSE to attend the Planet Microcap Showcase 2017, in Las Vegas on April 26-28. Linda Sampson and Yari Nieken, directors, will represent Marapharm. As an emerging company Marapharm will participate in one-on-one meetings, networking and will do a presentation to financial professionals, industry leaders, investors and executives. “We are honored to have been invited to participate in this event, it will give us the opportunity to share the Marapharm story alongside other keynote speakers in this sector,” Linda Sampson CEO.
All ground preparation and construction grading is complete at the site. We have altered the plans to accommodate our advanced vertical growing technology and as a result we have experienced some permitting delays. All permits are now ready to go, and construction will be expedited.
In the interim the Company has brought two modular buildings onsite which will be modified to meet Nevada State requirements for cultivation and processing. Upon Nevada State approval, the Company will be positioned to apply for recreational licensing, within the time frame of the new schedule as brought forward by the State of Nevada (July 2017). “We would like to thank the mayor of North Las Vegas, John Lee, and Nevada state officials for their assistance in helping us move our project forward. We invite shareholders to visit the construction site when in Las Vegas.” Linda Sampson CEO.
ABOUT MARAPHARM VENTURES INC.
Construction photos and videos can be accessed through the Marapharm website. Marapharms common shares are publicly traded in Canada, under the ticker symbol “MDM” on the Canadian Securities Exchange, and in the United States, under the ticker symbol “MRPHF” on the OTCQB, and in Europe, under the ticker symbol “2M0” on the FSE.
Marapharm has 300,000 square feet of medical marijuana licenses for its land and facilities in WA and NV. About two and a half years ago, Marapharm applied in Canada to Health Canada for a MMPR (production and sales) license and has passed the necessary security clearances. The application is currently in the in-depth screening process. In September 2016, Health Canada contacted Marapharm with a provision to amend its application to allow for the new regulations, ACMPR.
Additional information on the operations or financial results of Marapharm are included in reports on file with applicable securities regulatory authorities and may be accessed through the CSE website (www.thecse.com), the OTC website (www.otcmarkets.com), and the SEDAR website (www.sedar.com) under the profile for Marapharm Ventures Inc.
Neither the CSE, the FSE nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.
FORWARD – LOOKING STATEMENTS:
Certain statements contained in this news release constitute forward looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, ‘may”, “will”, “project”, “should”, ‘believe”, and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.